Why the study?
Mitral transcatheter edge-to-edge repair is approved for severe functional mitral regurgitation beyond optimal medical therapy, but its efficacy needed further evaluation.
Does TEER reduce heart failure hospitalization in patients with severe functional mitral regurgitation beyond optimal medical therapy?
Does TEER reduce heart failure hospitalization in patients with severe functional mitral regurgitation beyond optimal medical therapy?
In patients with severe functional mitral regurgitation, TEER added to optimal medical therapy significantly reduces heart failure hospitalizations and cardiovascular mortality while improving functional status.
Answers are grounded in this paper and cite their sources.
Supports adding TEER to OMT in severe functional MR; confirms RCT benefits on HFH and CV mortality.
BACKGROUND: Mitral transcatheter edge-to-edge repair (TEER) is approved for patients with severe functional mitral regurgitation (FMR) beyond optimal medical therapy (OMT). AIMS: We aimed to assess TEER's efficacy beyond OMT in patients with severe FMR. METHODS: A systematic review and meta-analysis were conducted, including randomized controlled trials from PubMed, Cochrane, Scopus, and EMBASE up to September 2024. PRIMARY OUTCOME: heart failure hospitalization (HFH); secondary outcomes: cardiovascular (CV) mortality, all-cause mortality, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. Time-to-event data from Kaplan-Meier curves were reconstructed for individual patient data. RESULTS: Three studies (1423 patients) were included. TEER significantly reduced HFH (RR 0.73, 95% CI 0.58-0.92, p < 0.01) and CV mortality (RR 0.79, 95% CI 0.66-0.95, p = 0.01), and improved KCCQ scores (mean difference 14.32, 95% CI 10.85-17.80, p < 0.01) compared to OMT. No significant difference was found for all-cause mortality (RR 0.80, 95% CI 0.63-1.02, p = 0.07). Prognostic meta-analysis showed a 34% reduced risk of HFH (HR 0.66, 95% CI 0.45-0.96, p = 0.03), but no effect on all-cause or CV mortality. Reconstructed Kaplan-Meier analysis confirmed a 34% reduced risk of HFH (HR 0.65, p < 0.001), with effect attenuation after 15 months in landmark analysis (HR 0.64, p = 0.07). RMST analysis showed a 2.9-month longer HFH-free survival with TEER (p < 0.01). CONCLUSION: In patients with FMR, TEER significantly reduces HFH, improves functional status, and lowers CV mortality at 24 months but does not significantly affect all-cause mortality. The device group experienced a modest, but significant, 2.9-month longer HFH-free survival compared to the control group. However, the reduction in HFH showed attenuation beyond 15 months.
No takes yet. Share an insight, caveat, or question.
Ghaly et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: